Skip to main content
GOSS
NASDAQ Life Sciences

Gossamer Bio Launches Distressed Debt Exchange, Proposes Massive Dilution & Reverse Split Amid FDA Progress

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
9
Price
$0.28
Mkt Cap
$79.797M
52W Low
$0.314
52W High
$3.87
52W Position info
11% below low
Off High info
93% below high
Rel. Volume info
0.4× avg
Market data snapshot near publication time

GOSS is trading near its 52-week low of $0.314 (11% below the low) on light trading volume (0.4× avg).

Summary

Gossamer Bio initiated a distressed debt exchange to cut $200M in convertible notes, proposing significant dilution and a reverse stock split to address financial distress and Nasdaq compliance, while also announcing positive FDA and clinical trial updates for seralutinib.


Key Events · Financing and Capital Events · GOSS

  • Distressed Debt Exchange Launched

    Gossamer Bio initiated an exchange offer for its $200 million 5.00% convertible notes due 2027, aiming to reduce outstanding debt to $72 million by issuing new 7.50% secured convertible notes, common stock, and warrants.

  • Massive Potential Dilution

    The exchange offer proposes to issue up to 317.6 million new shares and 150 million purchase warrants, representing a potential dilution of nearly 200% based on current outstanding shares.

  • Proposed Reverse Stock Split

    The company is seeking shareholder approval for a reverse stock split with a ratio between 1-for-10 and 1-for-150 to address its Nasdaq minimum bid price deficiency and maintain its listing.

  • Authorized Share Increase

    Shareholders will vote on increasing the authorized common stock from 700 million to 4 billion shares to accommodate the current exchange and future equity needs.


Analysis · GOSS · Life Sciences

This filing details a critical, multi-faceted strategy by Gossamer Bio to address its severe financial distress, including a reiterated going concern warning and Nasdaq delisting notice. The company is launching a distressed debt exchange to reduce $200 million in convertible notes to $72 million, but this comes with a proposal for massive potential dilution of nearly 200% through new shares and warrants. Concurrently, the company is seeking shareholder approval for a reverse stock split (up to 1-for-150) to regain Nasdaq compliance and a substantial increase in authorized shares from 700 million to 4 billion to enable future equity raises. These actions are necessary for the company's survival and continued listing, but represent a significant negative impact for existing shareholders. Amidst this financial restructuring, the company also announced positive news regarding its lead drug candidate, seralutinib, with a confirmed Pre-NDA meeting with the FDA and promising exploratory data from its Phase 3 PROSERA study, offering a potential path to approval and future revenue.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 52.4% of the 208 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.91%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, GOSS was trading at $0.28 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $79.8M. The 52-week trading range was $0.31 to $3.87. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

GOSS - Latest Insights

GOSS
Nov 10, 2026, 4:49 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $10.15
Real-time Price: $11.29 info
Change: +$1.14 (+11%) info
Market Cap: $69.054M info
GOSS
Sep 23, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $11.19
Real-time Price: $11.29 info
Change: +$0.0975 (+0.87%) info
Market Cap: $69.054M info
GOSS
Sep 23, 2026, 4:01 PM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $11.00
Real-time Price: $11.29 info
Change: +$0.290 (+3%) info
Market Cap: $69.054M info
GOSS
Sep 16, 2026, 4:30 PM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $10.93
Real-time Price: $11.29 info
Change: +$0.360 (+3%) info
Market Cap: $69.054M info
GOSS
Sep 11, 2026, 8:01 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.1562
Real-time Price: $11.29 info
Change: Reverse Stock Split info
Market Cap: $69.054M info